pimobendan has been researched along with Disease Models, Animal in 12 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 7.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| " Echocardiography results and invasive measurements of right and left ventricular systolic pressures were compared after 3-week administrations of sildenafil (S group), pimobendan (P group), nicorandil (N group), and their combinations (SP and SPN groups) in male rats with monocrotaline (MCT)-induced pulmonary hypertension (M group) and without this condition (C group)." | 7.81 | Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. ( Fukayama, T; Fukushima, R; Goya, S; Nakata, TM; Tanaka, R; Yoshiyuki, R, 2015) |
| "This study was designed to examine the effects of pimobendan in a murine model of viral myocarditis in relation to proinflammatory cytokine production and nitric oxide (NO) synthesis by inducible NO synthase (iNOS) in the heart." | 7.70 | Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. ( Iwasaki, A; Matsumori, A; Nishio, R; Okada, M; Ono, K; Sasayama, S; Shioi, T; Wang, W; Yamada, T, 1999) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 5.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| "Heart failure was induced in 20 dogs, to which pimobendan and two different doses of SCH00013 were administered orally to 15 dogs for 3 weeks, and the remaining 5 dogs served as the control." | 5.40 | Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure. ( Fukayama, T; Fukushima, R; Hamabe, L; Kawamura, K; Kim, SM; Shimizu, M; Tanaka, R; Yoshiyuki, R, 2014) |
| " To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection." | 3.91 | Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. ( Nakata, TM; Shimada, K; Suzuki, K; Tanaka, R; Uemura, A, 2019) |
| " Echocardiography results and invasive measurements of right and left ventricular systolic pressures were compared after 3-week administrations of sildenafil (S group), pimobendan (P group), nicorandil (N group), and their combinations (SP and SPN groups) in male rats with monocrotaline (MCT)-induced pulmonary hypertension (M group) and without this condition (C group)." | 3.81 | Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. ( Fukayama, T; Fukushima, R; Goya, S; Nakata, TM; Tanaka, R; Yoshiyuki, R, 2015) |
| "This study was designed to examine the effects of pimobendan in a murine model of viral myocarditis in relation to proinflammatory cytokine production and nitric oxide (NO) synthesis by inducible NO synthase (iNOS) in the heart." | 3.70 | Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. ( Iwasaki, A; Matsumori, A; Nishio, R; Okada, M; Ono, K; Sasayama, S; Shioi, T; Wang, W; Yamada, T, 1999) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 1.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| "Heart failure was induced in 20 dogs, to which pimobendan and two different doses of SCH00013 were administered orally to 15 dogs for 3 weeks, and the remaining 5 dogs served as the control." | 1.40 | Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure. ( Fukayama, T; Fukushima, R; Hamabe, L; Kawamura, K; Kim, SM; Shimizu, M; Tanaka, R; Yoshiyuki, R, 2014) |
| "Pimobendan is a so-called calcium sensitizer that exerts a positive inotropic action." | 1.31 | Effects of pimobendan and EGIS 9377, cardiotonic agents, and OG-VI, a nucleoside-nucleotide mixture, administered during reperfusion after ischemia on stunned myocardium in dogs. ( Fukutomi, T; Ichihara, K; Ogoshi, S; Satoh, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Nakata, TM | 2 |
| Suzuki, K | 1 |
| Uemura, A | 1 |
| Shimada, K | 1 |
| Tanaka, R | 3 |
| Hamabe, L | 1 |
| Kawamura, K | 1 |
| Kim, SM | 1 |
| Yoshiyuki, R | 2 |
| Fukayama, T | 2 |
| Shimizu, M | 1 |
| Fukushima, R | 2 |
| Nonaka, M | 1 |
| Morimoto, S | 2 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Li, L | 1 |
| Wang, YY | 2 |
| Arioka, M | 1 |
| Yoshihara, T | 1 |
| Takahashi-Yanaga, F | 2 |
| Sasaguri, T | 2 |
| Goya, S | 1 |
| Matsumori, A | 2 |
| Du, CK | 1 |
| Nishii, K | 1 |
| Minakami, R | 1 |
| Ohta, M | 1 |
| Tadano, N | 1 |
| Lu, QW | 1 |
| Zhan, DY | 1 |
| Mochizuki, M | 1 |
| Kita, S | 1 |
| Miwa, Y | 1 |
| Iwamoto, T | 1 |
| Ohtsuki, I | 1 |
| Solaro, RJ | 1 |
| Goto, Y | 1 |
| Hata, K | 1 |
| Iwasaki, A | 1 |
| Yamada, T | 1 |
| Shioi, T | 1 |
| Wang, W | 1 |
| Ono, K | 1 |
| Nishio, R | 1 |
| Okada, M | 1 |
| Sasayama, S | 1 |
| Fukutomi, T | 1 |
| Satoh, K | 1 |
| Ogoshi, S | 1 |
| Ichihara, K | 1 |
| Bitterman, H | 1 |
| Smith, BA | 1 |
| Lefer, AM | 1 |
1 review available for pimobendan and Disease Models, Animal
| Article | Year |
|---|---|
[Roles of cytokines in the pathogenesis of heart failure].
Topics: Animals; Antibodies, Monoclonal; Cytokines; Disease Models, Animal; Genetic Therapy; Heart Failure; | 2003 |
11 other studies available for pimobendan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Collagen Type I; Collagen Type III; Disease Models, Animal; Fibrosis; | 2019 |
Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure.
Topics: Administration, Oral; Animals; Calcium; Cardiotonic Agents; Dihydropyridines; Dilatation, Pathologic | 2014 |
Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cardiomyopathy, Dilated; Cardiotonic Agents; D | 2015 |
Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Hemodynamics; Hypertension, Pulmonary; H | 2015 |
Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation.
Topics: Amino Acid Sequence; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cell Membrane Pe | 2007 |
Translational medicine with a capital T, troponin T, that is.
Topics: Amino Acid Sequence; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cell Membrane Pe | 2007 |
Mechanoenergetic effect of pimobendan in failing dog hearts.
Topics: Animals; Cardiac Output, Low; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Dogs; In Vitro | 1997 |
Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis.
Topics: Animals; Cardiovirus Infections; Cytokines; Disease Models, Animal; Follow-Up Studies; Gene Expressi | 1999 |
Effects of pimobendan and EGIS 9377, cardiotonic agents, and OG-VI, a nucleoside-nucleotide mixture, administered during reperfusion after ischemia on stunned myocardium in dogs.
Topics: Adenosine Triphosphate; Animals; Cardiotonic Agents; Disease Models, Animal; Dogs; Heart; Hemodynami | 2000 |
Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock.
Topics: Animals; Cardiotonic Agents; Cathepsin D; Cats; Disease Models, Animal; Ischemia; Male; Myocardial D | 1988 |